InSCREENeX
InSCREENeX is a German biotech spin-off of the Helmholtz Centre for Infection Research that engineers custom and catalog stable and immortalized cell lines using proprietary Landing Pad and multi-gene immortalization technologies for pharmaceutical, biotechnology, and academic drug discovery customers.
- Company typePrivate
- Founded2009
- HeadquartersBraunschweig, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
What InSCREENeX does
InSCREENeX GmbH is a privately held German biotechnology company founded in 2009 as a spin-off of the Helmholtz Centre for Infection Research and headquartered in Braunschweig, Germany. The company specializes in engineered cell lines and cell line generation services for drug discovery and pharmaceutical research, serving pharmaceutical and biotechnology companies as its primary customer segment, with academic and research institutions as a secondary segment. Its portfolio is built around two proprietary core technologies developed by founders Dr. Roland Schucht and Tobias May during their PhDs: Landing Pad Technology, which uses recombinase-mediated site-specific, single-copy gene integration at pre-validated genomic loci to enable stable cell line generation and antibody libraries exceeding 10 million unique candidates; and a multi-gene cell immortalization approach using a custom lentiviral library that better preserves cell phenotype compared to traditional one- or two-gene methods. In February 2025 the company announced a collaboration with YUMAB GmbH to develop a Mammalian Display platform for antibody discovery, backed by €1M in Lower Saxony Innovation Funding and a €1.6M total project budget running until 2027.
The business operates three complementary revenue streams: custom cell line generation services (project-based, €3,000-€25,000 depending on complexity), off-the-shelf catalog cell lines priced on a tiered academic vs. industry basis (€900-€1,900 academic; €2,500-€8,200 industry), and supporting reagents and consumables (growth media, coating solutions, freezing media, FasTEER medium) specifically formulated for its cell lines. Distribution is via direct website inquiry and email, with additional presence on multiple digital B2B purchasing platforms for global enterprise procurement. Marketing and lead generation rely on a sales-led motion complemented by active participation in European biotech conferences (BIO-Europe, BIOSPAIN). The company remains founder-owned with no disclosed institutional venture capital, no external parent, and a headcount of 1-10 employees operating within Helmholtz Centre facilities.
InSCREENeX firmographics
Firmographics- Name
- InSCREENeX
- Legal name
- InSCREENeX GmbH
- Website
- https://inscreenex.de
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- InSCREENeX is a German biotech spin-off of the Helmholtz Centre for Infection Research that engineers custom and catalog stable and immortalized cell lines using proprietary Landing Pad and multi-gene immortalization technologies for pharmaceutical, biotechnology, and academic drug discovery customers.
- Ownership category
- akta.pro rank
InSCREENeX industry classification
Industry- Product category
- Cell Line Engineering Services and Reagents
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)
- akta.pro secondary industries
- Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH), Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)
Keywords
Where InSCREENeX is headquartered
LocationHeadquarters
- HQ city
- Braunschweig
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
InSCREENeX business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Custom Cell Line Generation Services: Project-based services for generating stable recombinant overexpression cells and immortalized functional cells. Pricing varies significantly by project complexity, ranging from €3,000-4,000 for basic polyclonal overexpression to €15,000-25,000 for complex monoclonal reporter cell lines.
- Off-the-Shelf Cell Lines: Sale of fully characterized stable and immortalized cell lines for research use. Includes CHO and HEK293 stable cell lines expressing various targets, and immortalized cells from multiple species.
- Reagents and Consumables: Sale of optimized cell culture media, coating solutions, and other consumables specifically formulated for company's cell lines.
- Licensing Royalties: Royalty-free license to IP for research use upon completion of service project. Separate commercial use licenses available for offering research services, release assays, or product incorporation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | Academic/Non-profit Research License - Immortalized Cell Lines |
| One time/ perpetual license | Pay-as-you-go | Industry Research License - Immortalized Cell Lines |
| One time/ perpetual license | Pay-as-you-go | Lower-cost Immortalized Cell Lines (Fibroblasts/Hepatocytes) |
| One time/ perpetual license | Pay-as-you-go | Porcine Nasal Epithelial Cells |
| One time/ perpetual license | Pay-as-you-go | Stable Recombinant Cell Lines (CHO/HEK293) |
| Other | Multi-year contract | Custom Stable Cell Line Generation - Basic Package |
| Other | Multi-year contract | Custom Stable Cell Line Generation - Standard/Monoclonal Package |
| Unit Pricing | Pay-as-you-go | Replacement/Additional Cell Vials |
Go-to-market motion2 records
Distribution channels2 records
Marketing channels5 records
InSCREENeX product offering
Product offeringCore offering
InSCREENeX designs and delivers custom and catalog cell lines for drug discovery and pharmaceutical research. Its core activities are (1) custom Stable Cell Line Generation using proprietary Landing Pad Technology or Random Integration, (2) custom Cell Immortalization using a proprietary multi-gene lentiviral library, and (3) sales of off-the-shelf characterized stable recombinant and immortalized cell lines together with optimized culture media, coating solutions, and freezing media. Customers are primarily pharmaceutical/biotech R&D groups and academic research institutions requiring functional, manufacturing-suitable cell models and reagents.
Product overview
InSCREENeX is a biotechnology company offering a comprehensive portfolio of cell biology products and custom services for drug discovery and research. The portfolio consists of three main pillars: (1) Custom Cell Line Generation Services including Stable Cell Line Generation using proprietary Landing Pad Technology or Random Integration approaches, and Cell Immortalization services using a custom lentiviral library; (2) Off-the-shelf Cell Line Products including Stable Recombinant Cell Lines (expressing targets like receptors, ion channels, immune checkpoints in CHO or HEK293 backgrounds) and Immortalized Cell Lines from human, mouse, and porcine sources covering diverse tissue types; and (3) Optimized Reagents and Consumables including specialized growth media, coating solutions, and freezing media formulated specifically for their cell lines. The company also announced a collaboration with YUMAB to develop a Mammalian Display platform for antibody discovery using their Landing Pad Technology.
Differentiator
Problem solved
Functional benefit
Products and services
- Custom Stable Cell Line Generation Service Custom generation of stable recombinant overexpression cell lines using proprietary Landing Pad Technology (site-specific single-copy gene integration) or Random Integration approaches; serves pharmaceutical and biotech customers needing target-expressing cell models.
- Custom Cell Immortalization Service Custom cell immortalization using a proprietary lentiviral library of immortalization genes, enabling primary cells to proliferate indefinitely while maintaining phenotype; serves researchers needing expanded access to functional primary cell models.
- Other Cell Services (Assay Development, Expansion, Banking) Ancillary cell services including assay development, cell expansion, and cell banking; serves customers needing complementary support around custom cell line and immortalization projects.
- Catalog Stable Recombinant Cell Lines (CHO-K1 / HEK293) Off-the-shelf, fully characterized stable overexpression cell lines in CHO-K1 and HEK293 backgrounds expressing targets including HER2, CTLA-4, CXCR4, CXCR7, FOLR1, B7H3, and TROP2; serves drug discovery and immuno-oncology researchers.
- Catalog Immortalized Cell Lines (Human, Mouse, Porcine) Off-the-shelf functional immortalized cell lines from multiple species (human, mouse, porcine) covering respiratory, digestive, endocrine, musculoskeletal, vasculature, and connective tissue cell types; serves academic and industry researchers needing characterized models.
- Cell Culture Reagents and Consumables Optimized cell culture media (for CHO, HEK293, and specialized immortalized cell types), coating solutions, cell freezing medium, and FasTEER assay medium formulated specifically for InSCREENeX cell lines; supports customers using the company's cell line products.
Quantifiable outcome
- 10-fold expected increase in efficiency for therapeutic antibody development using Mammalian Display platform
- +2 more outcomes
Companies that use InSCREENeX
Customer profileNamed customers1 record
Segments2 records
Ideal customer profiles2 records
InSCREENeX technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
InSCREENeX partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- YUMAB GmbHcoreCollaboration between inscreenex and YUMAB to develop Mammalian Display platform for antibody discovery. Funded under Lower Saxony Innovation Funding Program with €1.6M total budget and €1M in grant funding. Project runs until 2027. Platform enables efficient screening of large antibody libraries directly in mammalian cells for accelerated therapeutic antibody development.
- HIPS (Helmholtz Institute for Pharmaceutical Research Saarbrücken)minorCollaborative development of CI-hAELVi and CI-huArlo immortalized human alveolar epithelial cell lines. Both cell lines are results of collaboration between HIPS and inscreenex.
- HZI (Helmholtz Centre for Infection Research, Braunschweig)minorCollaborative development of CI-hAELVi immortalized human alveolar epithelial cell line in partnership with HZI.
- University and Policlinico San Matteo, Pavia (Italy)minorCollaborative development of CI-huEGC immortalized human enteric glial cell line.
- KU Leuven (Belgium)minorCollaborative development of CI-huEGC immortalized human enteric glial cell line.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
InSCREENeX competitors and assessment
Company assessmentDirect peers
- GenScript: Offers custom stable cell line services, gene synthesis, and protein expression for the same biotech/pharma market that InSCREENeX addresses. Overlapping technology stack around CHO/HEK293 line engineering and catalog reagent sales.
- ATCC: Largest global cell line repository, distributing authenticated research cell lines. Directly overlaps with InSCREENeX's catalog cell line business and the broader research-use cell line market.
- Eurofins Genomics: Provides cell line authentication, custom cell line engineering, and genomic services for research customers. Comparable to InSCREENeX in offering project-based gene-to-cell line services for European biotech/biopharma buyers.
- Applied Biological Materials (ABM): Provides cell lines, immortalization reagents (e.g., lentiviral immortalization kits), and custom cell line engineering services. Closest niche competitor to InSCREENeX's immortalization and stable line workflows for research customers.
- Lonza: Global leader in custom cell line development for biologics manufacturing (e.g., GS Xceed host lines). Directly competes with InSCREENeX's stable cell line generation services for pharma/biotech customers seeking production-grade recombinant lines.
- Horizon Discovery (Revvity): Specializes in gene editing and engineered cell lines for drug discovery and diagnostics, including custom stable line services. Competes head-on with InSCREENeX in the cell line engineering services space.
Broad incumbents
- Cellectis: Gene editing and cell engineering company with proprietary nucleases and engineered cell platforms. Technology-adjacent competitor in cell engineering IP and tools, but its focus is primarily therapeutic rather than research-only cell lines.
- AbCellera: Operates a leading antibody discovery platform using mammalian/phage display for therapeutic antibodies. Represents the scaled commercial version of the Mammalian Display platform InSCREENeX is co-developing with YUMAB.
- Thermo Fisher Scientific (Gibco/Invitrogen): Supplies cell lines, cell culture media, and reagents across a vast life sciences portfolio. Overlaps with InSCREENeX's catalog lines and consumables, but as part of a much broader offering rather than focused on custom cell engineering.
Emerging players
- YUMAB GmbH: Antibody discovery company and InSCREENeX's co-development partner on the Mammalian Display platform. Operates adjacent in the antibody discovery value chain rather than competing directly in cell line engineering services.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
InSCREENeX social profiles
Digital presenceInSCREENeX financial estimates
Financial estimateRevenue estimate
Valuation estimate
InSCREENeX leadership team
Management profileNumber of profiles
Profiles2 records
InSCREENeX funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
InSCREENeX M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about InSCREENeX
What does InSCREENeX do?
InSCREENeX designs and delivers custom and catalog cell lines for drug discovery and pharmaceutical research. Its core activities are (1) custom Stable Cell Line Generation using proprietary Landing Pad Technology or Random Integration, (2) custom Cell Immortalization using a proprietary multi-gene lentiviral library, and (3) sales of off-the-shelf characterized stable recombinant and immortalized cell lines together with optimized culture media, coating solutions, and freezing media. Customers are primarily pharmaceutical/biotech R&D groups and academic research institutions requiring functional, manufacturing-suitable cell models and reagents.
Is InSCREENeX a public or private company?
InSCREENeX is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was InSCREENeX founded?
InSCREENeX was founded in 2009. It employs 1 to 10 people.
Where is InSCREENeX based?
InSCREENeX is headquartered in Braunschweig, Germany, in the Europe region.
How does InSCREENeX make money?
Four revenue lines are on record. Custom Cell Line Generation Services are the primary driver. The others are off-the-Shelf Cell Lines, reagents and Consumables and licensing Royalties.
Who are InSCREENeX's main competitors?
Direct peers on record are GenScript, ATCC, Eurofins Genomics, Applied Biological Materials (ABM), Lonza and Horizon Discovery (Revvity). Broad incumbents are Cellectis, AbCellera and Thermo Fisher Scientific (Gibco/Invitrogen). YUMAB GmbH is listed as an emerging player.
Does InSCREENeX have an API?
No public API is recorded for InSCREENeX.
What industry is InSCREENeX in?
InSCREENeX's product category is Cell Line Engineering Services and Reagents. Its primary akta.pro industry code is HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods), with a secondary code of HLAAABAH, Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables). Its NAICS code is 325414 and its SIC code is 2836.